Novartis grants Tasigna rights to MPP for generics in LMIC countries

20 October 2022
2020_novartis_big

Swiss pharma giant Novartis (NOVN: VX) has entered into a voluntary licensing agreement for its chronic myeloid leukemia (CML) drug with the Medicines Patent Pool (MPP), agreeing to the production of generics in low-and-middle income countries.

The MPP announced on the side-lines of the World Cancer Congress that the accord would increase access to nilotinib, a twice daily oral medicine used to treat CML, part of the World Health Organization Model List of Essential Medicines (WHO EML), for the treatment in adults and children of at least one year of age.

Marketed as Tasigna, the drug generated sales of $2.1 billion for Novartis last year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics